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Abstract Glargine is an analog of Insulin currently being
produced by recombinant DNA technology using two
different hosts namely Escherichia coli and Pichia
pastoris. Production from E. coli involves the steps of
extraction of inclusion bodies by cell lysis, refolding,
proteolytic cleavage and purification. In P. pastoris, a
single-chain precursor with appropriate disulfide bonding
is secreted to the medium. Downstream processing cur-
rently involves use of trypsin which converts the precur-
sor into two-chain final product. The use of trypsin in the
process generates additional impurities due to presence of
Lys and Arg residues in the Glargine molecule. In this
study, we describe an alternate approach involving over-
expression of endogenous Kex2 proprotein convertase,
taking advantage of dibasic amino acid sequence (Arg-
Arg) at the end of B-chain of Glargine. KEX2 gene over-
expression in Pichia was accomplished by using pro-
moters of varying strengths to ensure production of great-
er levels of fully functional two-chain Glargine product,
confirmed by HPLC and mass analysis. In conclusion,
this new production process involving Kex2 protease
over-expression improves the downstream process effi-
ciency, reduces the levels of impurities generated and
decreases the use of raw materials.
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Introduction
Insulin Glargine (also referred as Glargine) is a slow acting
analog of Insulin. It is similar in structure to Insulin, except for
the replacement of A21 amino acid from asparagine to glycine
in A-chain and the addition of two positively charged arginine
(RR) residues at the C-terminus of B-chain. These changes
shift the isoelectric point towards neutrality and result in
micro-precipitation of Glargine at the site of injection.
Glargine, administered by subcutaneous route, has duration
of action of 24 h with no peak and gives good glycaemic
control. It has lesser incidence of nocturnal hypoglycaemia
(Poon and King 2010). Two recombinant microbial hosts are
being employed for commercial manufacturing namely
Escherichia coli and Pichia pastoris. In E. coli, the
manufacturing process involves lysis of cells, recovery of
inclusion bodies, refolding and cleavage of the peptide
connecting A- and B-chains to yield two-chain product
(Zimmerman et al. 2012).
In P. pastoris, Glargine is expressed as a secreted single-
chain precursor consisting of N-terminal B-chain followed by
A-chain with no connecting peptide. The Glargine precursor is
treated with trypsin to separate A- and B-chains and is con-
verted to the two-chain product (Hazra et al. 2009). The A and
B-chains are connected by two disulfide bridges. Trypsin has
the specificity to cleave at the C-terminus of both lysine and
arginine residues (Olsen et al. 2004). Since, Glargine B-chain
sequence has internal lysine and arginine residues, a number
of fragmented impurities are generated following trypsin treat-
ment. In an attempt to improve the downstream process effi-
ciency, we have explored the advantage of using Kex2 prote-
ase (Kex2p), which cleaves specifically at the C-terminus of
S. Sreenivas (*) :N. Govindappa :Y. Basavaraju :K. Kanojia :
N. Mallikarjun : J. Natarajan :A. Chatterjee :K. N. Sastry
Biocon Research Limited, Plot No.2&3, Phase IV,
Bommasandra-Jigani Link Road, Bangalore 560099, Karnataka,
India
e-mail: suma.sreenivas@biocon.com
S. M. Krishnaiah
Molecular Diagnostics Laboratory, Dept. of Microbiology &
Biotechnology, Bangalore University, JnanaBharathi Campus,
Bangalore 560056, Karnataka, India
Appl Microbiol Biotechnol (2015) 99:327–336
DOI 10.1007/s00253-014-6052-5
dibasic amino acid residues KR and RR (Germain et al. 1992).
Glargine has a unique primary amino acid sequence where the
B-chain ends with dibasic amino acid sequence ‘RR’ which
can be cleaved specifically by Kex2p converting the single-
chain precursor to the two-chain product. Engineering the
P. pastoris strain with increased levels of Kex2p would enable
the in vivo processing and could lead to increased levels of
two-chain Glargine in the medium.
The Saccharomyces cerevisiae Kex2 protease (also known
as Kexin; EC 3.4.21.61) is a Ca2+-dependent serine protease
of subtilisin-like proprotein convertase family (Mizuno et al.
1989). It is encoded by the KEX2 gene and is an endoprotease.
It is well known that the yeast endoprotease Kex2p removes
the signal peptides from the pre-proteins and releases the
mature form of secreted proteins and thus plays a pivotal role
in yeast secretory pathways. The high specificity of Kex2p is
in contrast to the other members of the subtilisin family which
are known to be degradative in their action. Kex2p and its
mammalian homologues Furin (van den Ouweland et al.
1990), PC2 (Smeekens and Steiner 1990; Seidah et al. 1990)
and PC3 (Smeekens et al. 1991; Seidah et al. 1991) are similar
to each other than to the degradative subtilisins. The Kex2p
can be secreted by deleting the transmembrane domain and
the C-terminal tail region without affecting the activity of the
protease (Brenner and Fuller 1992). In our study, we have
used P. pastoris Kex2 proprotein convertase (UniProtKB/
Swiss-Prot Q5J881). The gene encoding Kex2p has been
identified in Pichia genome and has been annotated based
on homology to the S. cerevisiae KEX2 gene (De Schutter
et al. 2009). We have used a shorter version of the KEX2 gene
for our study after deleting the C-terminal region.
When Glargine was expressed in P. pastoris, approximate-
ly 3 % of the recombinant protein is secreted as two-chain
Glargine, after endogenous Kex2p cleavage at C-terminus of
‘RR’ sequence, while the rest is secreted as a single-chain
precursor. We hypothesized that the level of Kex2p was not
sufficient to carryout complete conversion of all the expressed
molecules. The aim of this study was to determine if the
majority of single-chain precursor can be converted to two-
chain Glargine in vivo. Here, we report engineering of the
P. pastoris genome by inserting additional copies of KEX2
gene expression cassettes with promoters of varying strengths
to increase the process efficiency. Plasmid constructs were
developed by fusing the KEX2 gene in frame with the
strong constitutive glyceraldehyde-3-phosphate dehydro-
genase (GAP) promoter (Waterham et al. 1997) and
inducible formaldehyde dehydrogenase (FLD1) promoter
(Duan et al. 2009). These constructs were introduced to
the P. pastoris host expressing Glargine precursor. The
conversion of the precursor to the two-chain product was
monitored by HPLC analysis of the supernatant, and the
authenticity of the product was confirmed by peptide
mass fingerprint analysis.
Materials and methods
Strains, plasmids and media
The P. pastoris strain GS115 (ATCC 20864) was used for
expression of Glargine. The expression vector used was
pPIC9K (Invitrogen, CA, USA) that provides the AOX1 pro-
moter and terminator sequences and the S. cerevisiae Mat-α
signal sequence for secretion. The pPICZAvector (Invitrogen,
CA, USA) was modified for the cloning of the Kex2p coding
sequence in frame with different promoters. All yeast cultures
were grown at 30 °C. The E. coli strain DH5α was used for
routine cloning and propagation of plasmids. Yeast extract-
peptone-dextrose (YPD) medium (containing per liter: 10 g
yeast extract, 20 g peptone, and 20 g dextrose) was used for
routine growth and sub-culturing of P. pastoris strains. YNBD
agar plates (containing per liter: 13.4 g yeast nitrogen base
without amino acids, 20 g dextrose and 20 g agar) was used
for selection of the transformants. Luria broth/agar was used
for culturing E. coli. Media components used were either from
Himedia (Mumbai, India) or Difco (Becton, Dickinson and
Company, MD, USA).
Construction of recombinant plasmids for expression
in P. pastoris
The Glargine nucleic acid sequence was codon optimized for
expression in P. pastoris. The synthetic Glargine coding gene
was obtained from Geneart Inc., Germany. The gene was sub-
cloned into the Pichia expression vector pPIC9K between
XhoI and EcoRI sites. The resulting construct Glargine/
pPIC9K (Fig. 1a) was verified by sequencing the gene of
interest.
The Kex2p expression cassettes were developed by cloning
KEX2 gene 660 amino acid coding sequence (UniProtKB/
Swiss-Prot Q5J881, M1 to D660) in frame with different
promoters and cloned in pPICZA vector. The P. pastoris
GS115 (ATCC 20864) genomic DNA was used as template
for PCR amplifications. Briefly, the 477 bp GAP promoter
was amplified by PCR using primers GAPFP and GAPRP.
The 1980 bp KEX2 gene (NCBI Reference Sequence:
XM_002491154, +1 to +1980) was amplified by PCR using
primers KexFP1 and KexRP1. The amplified products of
GAP promoter and KEX2 gene were gel purified (Qiagen,
Germany) and used as template to generate the GAP-KEX2
gene construct (Fig. 1b) by overlap PCR (Yon and Fried 1989)
using primers GAPFP and KexRP1. It was cloned into
pTZ57R vector (MBI Fermentas, Germany) and sequence
verified. The GAP promoter-KEX2 gene-fused DNA frag-
ment was later cloned into the pPICZA vector between the
BglII and EcoRI restriction sites. Similarly, using the GS115
genomic DNA, the FLD1 promoter was amplified by PCR
using primers FLDFP and FLDRP and the KEX2 gene was
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amplified using the primers KexFP2 and KexRP2. The am-
plified gene products were purified using gel extraction kit
and used as template to carry out overlapping PCR using
primers FLDFP and KexRP2 (Fig. 1c). The FLD1 promoter-
KEX2 gene-fused DNA fragment was cloned to the pPICZA
vector between the BglII and NotI sites. The primers sequence
details are provided in Table 1. Expand High fidelity PCR
system (Roche Diagnostics, GmbH, Germany) was used for
all the PCR amplification steps.
Transformation of Glargine/pPIC9K plasmid into P. pastoris
The expression construct Glargine/pPIC9K (Fig. 1a) was lin-
earized with SacI restriction enzyme (New England Biolabs,
USA) and transformed into histidine auxotrophic P. pastoris
strain GS115. Transformation was carried out by electropora-
tion of freshly grown cells in 0.2-cm cuvette. The pulse was
delivered by Gene Pulser (Bio-Rad Laboratories Inc., USA) at
2000 V, 25 μF and 200 Ω. The electroporated cells were
allowed to recover for 1 h in 1 M sorbitol at 30 °C and then
Fig. 1 aMap of Glargine/
pPIC9K vector showing the
Glargine nucleic acid sequence
cloned between the XhoI and
EcoRI restriction sites in frame
with the AOX1 promoter. It con-
tains the HIS4 ORF for metabolic
selection in P. pastoris host. The
unique SacI site was used for lin-
earizing the vector prior to trans-
formation. b The schematic rep-
resentation of GAP promoter and
the KEX2 gene products assem-
bled by PCR and was sub-cloned
to pPICZA vector between the
BglII and EcoRI restriction sites.
The restriction enzyme NheI was
used for linearizing prior to trans-
formation. b The caption of FLD1
promoter and the KEX2 gene
products which were assembled
by PCR and further sub-cloned to
pPICZAvector between BglII and
NotI restriction sites. The restric-
tion enzyme BspHI was used for
linearizing the construct before
transformation to P. pastoris host
Table 1 List of primers used in the study
Primer Sequence (5′ to 3′)
GAPFP GGATCC GCTAGC GCTAGC TTT TTG TAG
AAATGT C
GAPRP GGC AAATAC ATATAG TTG TTC AAT TGA
TTG AAAT
KexFP1 TTG AAC AAC TATATG TAT TTG CCA GCA CTT CGC
KexRP1 GAATTC CTTAAT CAC CGG TTG TAG AAG TCT C
FLDFP GCG GAT CCG CAT GCA GGA ATC TCT GGC ACG G
FLDRP CTG GCA AATACATTG TGA ATATCA AGA
ATT GTAT
KexFP2 CTT GATATT CAC AAT GTATTT GCC AGC
ACT TCG C
KexRP2 GCG GCC GCT TAATCA CCG GTT GTA GAA GTC TC
IGPFP CAT TGT TCA ACA ATA CCT CTT CTA G
IGPRP CAT TTG TGT GGT TCT CAT TTG G
GAPQFP ATG ACC GCC ACT CAA AAG AC
GAPQRP GCA CCA GTG GAA GAT GGA AT
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spread on YNBD agar plates. The resulting transformants
were screened on YPD plates containing progressively in-
creasing concentrations of G418 (0.5–2.0 mg/ml) to identify
multicopy clones. Several clones that were viable at 2 mg/ml
concentration were selected for productivity check in small
scale induction experiments. Culture supernatant samples
were analysed by HPLC to identify the best expressing clone.
Induction of Glargine expression in P. pastoris
The selected transformants were grown in 10 ml YNBD
medium (1.34 % yeast nitrogen base w/o amino acids and
2 % dextrose) overnight. It was next sub-cultured to 50 ml
BGMY (1 % yeast extract, 2 % peptone, 1.34 % YNB,
100 mM potassium phosphate at pH 6.0 and 1 % glycerol)
at a concentration of 0.5 OD600. This culture was incubated at
30 °C for 48 h with shaking at 220 rpm. The cells were
harvested by centrifugation at 5000 rpm for 5 min at room
temperature and the cell pellet was resuspended in induction
medium (1 % yeast extract, 2 % peptone, 1.34 % YNB and
100 mM potassium phosphate at pH 6.0). Methanol (20 %
stock) was added to the culture medium for induction of
protein expression at a final concentration of 1 %. The induc-
tion was carried out for 4 days with methanol being added to
the medium once every 24 h. The cell-free supernatant sam-
ples were collected every day and analysed by HPLC.
Transformation of the Kex2p/pPICZA constructs
to Glargine-producing P. pastoris host
The constructs corresponding to promoter-KEX2 gene fusions
(Fig. 1b, c) were linearized by digesting with the restriction
enzymes NheI and BspH1 respectively and were independent-
ly transformed to the Glargine-producing P. pastoris host. The
transformation procedure used was the same as described
above, except that after allowing cells to recover in 1 M
Sorbitol, one volume of YPD medium was added and the
culture was incubated for 1 h at 30 °C. Cells were then plated
on YPD medium supplemented with 1 M sorbitol and
100 μg/ml Zeocin (Life technologies, USA). The
transformants obtained were screened for higher Zeocin resis-
tance. The colonies resistant to 1 mg/ml Zeocin were chosen
for induction and evaluation of two-chain Glargine secretion.
Estimation of copies of Glargine gene using GAP gene
as a single-copy housekeeping reference
The Glargine gene copy was determined by quantitative real-
time PCR (QPCR) using relative quantitationmethod (Li et al.
2004). The single-copyGAP gene in Pichia genome was used
as the reference gene to determine the integrated Glargine
gene copies. The QPCR was set up using primers GAPQFP
and GAPQRP for amplification of the GAP gene and IGPFP
and IGPRP for amplification of the Glargine gene. The geno-
mic DNA template concentration of 1, 10, 100, 1000 and
10,000 picograms were used to obtain consensus results.
SYBR green chemistry was used for monitoring the amplifi-
cation and data acquisition.
HPLC assay
HPLC assay for measuring the levels of Glargine precursor as
well as the two-chain Glargine product were performed using
C18 column (250×4.6 mm; 5 μm fromACE) under a gradient
run. The mobile phase consisted of A 0.1 % trifluoroacetic
acid (TFA) (75 %) and B 25 % acetonitrile. The runtime was
18 min where the component B composition decreased from
75 to 60 % in 15 min at a flow rate of 1.0 ml/min. A sample
volume of 50 μl was injected into the column maintained at
40 °C, and the sample was monitored at 220 nm.
Liquid chromatography/mass spectrometry
The Glargine sample from shake flask fermentation was puri-
fied on semi-preparative reverse phase HPLC method in
Agilent 1200 chromatography system (Agilent, CA, USA)
using Supelco Discovery BIO Wide Pore C18 reverse phase
column (250×10 mm, 5 μm). About 200 μg of crude protein
was loaded on to the column, and temperature was maintained
at 40 °C. The eluents were monitored at 214 nm, and the peak
corresponding to Glargine was purified up to 98 %. The
purified sample was lyophilized under vacuum and used for
analysis.
From the lyophilized powder, about 1 mg/ml of
Glargine was dissolved in 0.01 N HCl and complete
physico-chemical characterization was done in comparison
with commercially available Lantus®. Identification of
Glargine was carried out on Thermo Scientific LTQ
Orbi t rap coup led wi th chromatography sys tem
(Shimadzu, DGU-20A model, Japan) using ACE symme-
try C18 column (250×4.6 mm, 5 μm). The mobile phase
solvents consisted of A 0.1 % TFA and B 100 % acetoni-
trile. The purified Glargine sample was eluted using a
linear gradient program with initial 25 % of B and eluted
with 37 % of acetonitrile with the flow rate of 0.7 ml/min.
About 5 μl of sample (Glargine or Lantus®) was injected to
the column maintained at 40 °C, and the eluents were
monitored at 214 nm. The mass spectrometer was operated
in electrospray ionization (ESI) positive ionization mode
with the following mass spectrometry parameters: source
voltage of 3.5 kV and capillary temperature of 340 °C. The
sheath gas flow was kept at 40, aux gas flow at 20, and the
scan was performed in the mass range 700–2200 Da, and
the data acquired from Orbitrap (FT) was analysed.
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Peptide mass fingerprint analysis
Both Glargine and Lantus® were digested with endoprotease
Glu-C with a sample: enzyme w/w ratio of 1:40. For this,
100 μl (1 mg/ml) of protein was first pH adjusted to 7.5 using
Tris buffer (pH 8.0) followed by the addition of Glu-C prote-
ase. The reaction mixture was incubated at 37 °C for 4 h. The
digested samples were reduced using 5 μl of 1 M DTT and
incubated at 37 °C for 30 min. Further analysis was performed
on both non-reduced and reduced digested sample, to confirm
disulfide bridge connectivity and sequence information.
Digested samples were separated on a Waters Symmetry
C18 column (250×4.6 mm, 5 μm) at a flow rate of 0.7 ml/min
using the gradient program 0–60 min, 5–80 % B, solvent A
0.1 % aqueous TFA and solvent B 95 % acetonitrile, and
column temperature was maintained at 40 °C. A sample
Fig. 2 Strategy for direct secretion of two-chain Insulin Glargine in
P. pastoris. a The amino acid sequence of Insulin Glargine used in this
study where the B-chain (shown in bold) is followed by the A-chain
sequence. The amino acids underlined are the lysines and arginines
susceptible to trypsin cleavage. The codon-optimized nucleotide
sequence for expression in P. pastoris is shown below the corresponding
amino acids. b Cartoon representation of the steps in the conversion of
precursor to final product by conventional method using trypsin in
comparison to the use of Kex2p
Appl Microbiol Biotechnol (2015) 99:327–336 331
volume of 25 μl was injected, and peaks eluted were moni-
tored at 214 nm. The thus separated Glu-C-digested peptides
were further analysed by ESI-MS in order to generate peptide
mass fingerprint data.
Results
Strategy and construction of expression plasmids
The amino acid sequence and the codon-optimized nucleotide
sequence of Glargine used in the study are shown in Fig. 2a
where the B-chain (marked in bold) ends with RR and is
followed by the A-chain without any connecting C-peptide.
Also marked are the trypsin-susceptible lysines and arginines
present in the B-chain, which have been underlined. Figure 2b
represents the outline of the strategy.Marked in the figure with
arrows are the potential Kex2p cleavage sites. The Glargine
coding sequence was cloned in the pPIC9K vector in frame
with the Mat-α signal sequence to enable secretion of the
protein. The KEX2 gene was fused to the C-terminus of
different promoters by PCR and cloned into the pPICZA
vector. All the constructs were verified by sequencing and
were linearized prior to transformation to the P. pastoris host.
Expression of Glargine in P. pastoris host
The Glargine/pPIC9K construct (Fig. 1a) was transformed
into the P. pastoris GS115 strain. The colonies which showed
resistance to 2 mg/ml of G418 were confirmed by PCR for the
presence of the Glargine coding sequence integrated into the
genome. The clones selected were screened for the Glargine
productivity by methanol induction as described previously in
shake flasks. Clone #9F12 consistently produced higher quan-
tity of Glargine. Copy number analysis of this clone was
performed by QPCR as described earlier. The QPCR experi-
ment raw data was analysed for the linearity of the standard
curve for both Glargine and endogenous P. pastoris GAP
genes (Fig. 3a). The correlation coefficients for the GAP and
the Glargine genes were 0.9994 and 0.9998, respectively. On
analysis of the melt curve, the Tm for GAP and Glargine gene
products are 81.05 °C and 76.61 °C, respectively. The gene
copy index (GCI) was found to be 3. The Ct values obtained
using various DNA concentrations are shown in Table 2. The
Glargine secreted to the medium was analysed using HPLC
method as described previously, and the chromatogram ob-
tained is shown in Fig. 4a. The major peak observed at the
retention time (RT) of 9.8–10 min corresponds to the Glargine
precursor species. The productivity of Glargine precursor was
found to be 56.3 mg/l. The two-chain Glargine product se-
creted to the medium was only 1.25 mg/l.
Intracellular expression of Kex2p using GAP promoter
The P. pastoris clone #9F12 producing Glargine was trans-
formed with Kex2p construct (Fig. 1b) where a constitutive
GAP promoter was used for the expression of KEX2 gene.
Colonies which grew on 1 mg/ml of Zeocin were selected for
evaluation of the levels of two-chain Glargine in the medium.
Cell-free supernatants of induced cultures were analysed by
HPLC. The chromatogram showed the presence of both
Fig. 3 QPCR data analysis for determination of the GCI of Glargine
(clone #9F12). a The standard curve forGlargine andGAP genes. The R2
of the standard curve obtained for both the genes are 0.9994 and 0.9998,
respectively. b The melt curve obtained for the GAP and the Glargine
genes shows a specific melting temperature (Tm) for each gene indicating
specific product formation
332 Appl Microbiol Biotechnol (2015) 99:327–336
precursor and two-chain Glargine species (Fig. 4b). The peak
which is between RT of 9.8–10 min was the precursor
Glargine species, and the peak between RT of 11.5–11.8 min
corresponds to the processed two-chain Glargine.
Intracellular expression of Kex2p using FLD1 promoter
The Glargine-secreting P. pastoris clone #9F12 was trans-
formed with Kex2p construct (Fig. 1c) where strong inducible
FLD1 promoter was fused in frame with the KEX2 gene.
Colonies which grew on 1 mg/ml of Zeocin were evaluated
for two-chain Glargine levels in the medium. The clones were
induced using methanol, and the day 4 samples were analysed
by HPLC. The HPLC profiles of the cell-free supernatant
indicated that the major peak at RT of 11.5–11.8 min corre-
sponds to the two-chain Glargine species (Fig. 4c).
Table 2 Results of the GCI analysis for Glargine gene by QPCR
Concentrations of DNA Ct Glargine Ct GAP Δ Ct Average Δ Ct
10 ng 13.72 16.82 3.1 3.12
1 ng 16.81 19.88 3.07
100 pg 19.88 23.06 3.18
10 pg 23.17 26.30 3.13
The Ct values obtained for the PCR amplification of Glargine gene and
the single-copy endogenous GAP gene using different genomic DNA
concentrations of P. pastoris clone #9F12.Δ Ct is the difference in the Ct
values between Glargine and GAP gene. AverageΔ Ct is the average of
the Δ Cts obtained for each DNA concentration
Fig. 4 a HPLC chromatogram of
cell-free supernatant of P. pastoris
strain expressing Glargine (clone
#9F12). The peak marked by an
arrow at the left shows the prom-
inent single-chain precursor being
secreted by the host. The peak
marked at the right shows very
low levels of the two-chain
Glargine. b HPLC chromatogram
of cell-free supernatant of
P. pastoris strain (clone #9F12)
with intracellular co-expression of
Kex2p using GAP promoter
which shows conversion of
∼50 % precursor to two-chain
Glargine. c HPLC profile of the
cell-free supernatant of P. pastoris
strain (clone #9F12) with intra-
cellular co-expression of Kex2p
using strong FLD1 promoter,
showing >90 % two-chain
Glargine
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Mass spectroscopy analysis
The two-chain Glargine secreted from the clone #9F12 with
Kex2p over-expressed using FLD1 promoter was analysed by
mass spectroscopy in comparison with Lantus®. The
deconvoluted mass spectrum of the sample showed the mass
to be 6063.9 Da (M+H)+.
The peptide mass fingerprint analysis results for Glargine
sample was compared to that of Lantus®. It was observed that
the converted two-chain Glargine sequence matches exactly
with the Lantus® in terms of mass-based identities of the Glu-
C-digested peptides. This confirms that once the Kex2p
cleaves at the C-terminal of RR sequence at the end of B-
chain, the completely processed two-chain Glargine is secret-
ed to the medium. Figure 5 shows the results of the peptide
mass fingerprint data, where the Glargine precursor sample
from the shake flask is compared to Lantus®. The peaks
corresponding to the different peptides from Glargine corre-
lated well with that of Lantus®. The data of the identity of the
different peptides under non-reduced and reduced conditions
when the samples are digested with Glu-C is depicted in
Tables 3 and 4, respectively.
Discussion
The methylotrophic yeast P. pastoris has been proven to be a
suitable host for production of recombinant proteins
(Cereghino and Cregg 2000; Cregg et al. 2000). We expressed
single-chain Glargine precursor in the yeast P. pastoris as a
secreted protein using the Mat-α signal sequence. It was
secreted mostly as a single-chain precursor and was converted
to the two-chain product by a process which involved the use
of trypsin. We have explored the use of Kex2p for the pro-
cessing of the Glargine precursor in vivo to secrete the two-
chain molecule to the medium. The Glargine amino acid
sequence presents an opportunity where the enzymatic activ-
ity of Kex2p can convert the precursor to the final two-chain
Glargine molecule. It was observed that when Glargine pre-
cursor was expressed in the P. pastoris host (clone #9F12);
only about 3 % of the precursor was processed into two-chain
Glargine, and the rest of the secreted recombinant protein was
the single-chain precursor (Fig. 4a). This result indicated that
endogenous Kex2p produced is insufficient to complete this
process. Limitations in the amount of Kex2p on intracellular
expression were also reported (Seeboth and Hein 1991). Co-
expression of the truncated version of Kex2p resulted in the
correct processing of the Rhizopus oryzae lipase in
Fig. 5 The total ion chromatogram of peptide mass fingerprint analysis
of Glargine in comparison to Lantus®, showing the elution of different
peptides with respective RTs. a The endoprotease Glu-C digest of the
samples shows four expected peptides for Glargine (top) and Lantus®
(bottom). b DTT reduced endoprotease Glu-C digest which shows the
presence of six expected peptides of Glargine (top) and Lantus® (bottom).
The sequence was further confirmed by low energy CIDMS/MS, and the
data is shown in Tables 3 and 4, respectively
Table 3 Theoretical and observed peptides following endoprotease Glu-C digest of Glargine and Lantus®
Peptide
no.
Peptide range RT of Glargine
and Lantus® (min)
Theoretical
mass (M+H)+ (Da)
Observed mass
(M+H)+ (Da)
Sequence Linked peptide
Glargine Lantus®
I A (1–4) 10.64 417.2 417.24 417.23 GIVE –
II B (22–32) 14.83 1428.8 1428.79 1428.79 RGFFYTPKTRR –
III A (18–21) and
B (14–21)
21.28 1320.6 1320.57 1320.56 (NYCG) and (ALYLVCGE) Disulfide linkage between
A20 and B19
IV A (5–17) and
B (1–13)
34.45 2968.30 2968.34 2968.34 (QCCTSICSLYQLE) and
(FVNQHLCGSHLVE)
Disulfide linkage between
A6-A11 and A7-B7
The linked peptide confirms the appropriate disulfide connectivity. The mass in the table represents monoisotopic mass
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S. cerevisiae (Takahashi et al. 2000). Therefore, an effort to
improve the conversion efficiency was initiated by over-
expression of Kex2p in the P. pastoris clone #9F12. We
expressed the truncated version of the Kex2p (M1 to D660)
secreting into the medium in Glargine-producing P. pastoris
clone #9F12 under the regulatory control of GAP promoter.
The secreted Glargine sample was analysed by HPLC and
found that the conversion of the precursor to the two-chain
Glargine product was not enhanced (data not shown). This
might be possibly due to accessibility, and conditions preva-
lent in the medium may not be optimal for the functional
activity of the Kex2p. So, the over-expression of the Kex2p
intracellularly to improve the processing efficiency was
attempted. It has been reported that an incorrectly processed
IFNα-2a molecules were secreted from the precursor with N-
terminal extensions of the mature protein when expressed in
Hansenula polymorpha (Muller et al. 2002). Correct process-
ing was observed when KEX2 gene was over-expressed in the
same host using its native promoter. The yields of many
recombinant proteins were greatly influenced by Kex2 P1′
site residues, and the optimized residue could determine the
final amount of secretory protein. A further improvement of
the yield can be accomplished by integration of additional
copies of KEX2 gene (Yang et al. 2013).
In this study, we initially used a constitutiveGAP promoter
for intracellular expression of Kex2p in the P. pastoris host
secreting Glargine. Approximately 40–60 % of two-chain
Glargine species was detected extracellularly (Fig. 4b) indi-
cating that the intracellular over-expression of Kex2p was
enhancing the conversion. But the quantity of protease pro-
duced using GAP promoter was still not sufficient to achieve
complete processing. Hence, in order to improve the conver-
sion efficiency, the Kex2p was co-expressed intracellularly
with strong inducible FLD1 promoter which is also induced
by methanol in the Glargine-producing host. In this case,
>90 % of the secreted recombinant protein was found to be
the two-chain Glargine. The copy number of the KEX2 gene
integrated using different promoter’s influenced the produc-
tion of recombinant protein; hence, neglecting the gene copy
numbers can lead to incorrect interpretation of the results
(Abad et al. 2010). Therefore, an attempt was made to under-
stand whether the improvement in efficiency of conversion
using FLD1 promoter-drivenKEX2 gene is due to higher copy
numbers integrated or due to the relative promoter strength.
GCI of KEX2 gene cassettes integrated using the GAP and
FLD1 promoters was determined. Relative quantitation was
performed using protocol similar to the one used for deter-
mining the copy number of Glargine gene. The GCI of KEX2
gene was found to be two for both GAP and FLD1 promoter-
driven Kex2p over-expressing host strains (data not shown).
The Kex2p over-expressing clones have same copies of the
cassette integrated in the genome. This result indicates that the
increase in the conversion rates is due to the difference in the
promoter’s strength.
The two-chain Glargine species that was secreted from
FLD1 promoter-KEX2 gene over-expressing host was charac-
terized by mass analysis and peptide mass fingerprinting. It
was compared to the commercially available Lantus®. The
Table 4 Theoretical and observed peptides of endoprotease Glu-C digestion followed by DTT reduction of Glargine and Lantus®
Peptide no. Peptide range RT of Glargine and Lantus® (min) Theoretical mass (M+H)+ (Da) Observed mass (M+H)+ (Da) Sequence
Glargine Lantus®
I A (18–21) 6.70 456.1 456.16 456.16 NYCG
II A (1–4) 10.63 417.2 417.24 417.24 GIVE
III B (1–13) 16.59 1482.7 1482.73 1482.73 FVNQHLCGSHLVE
IV B (22–32) 14.80 1428.8 1428.80 1428.81 RGFFYTKPTRR
V B (14–21) 26.65 867.4 867.43 867.43 ALYLVCGE
VI A (5–17) 35.90 1490.6 1490.64 1490.64 QCCTSICSLYQLE
The sequence of all the peptides was confirmed by CID MS/MS. The mass in the table represents monoisotopic mass
Table 5 Quantitative estimation of % of two-chain Glargine levels from Glargine-expressing P. pastoris hosts with Kex2p over-expression
Clone Precursor peak
area (A)
Two-chain Glargine
peak area (B)
Total area
C=(A+B)
% two-chain
Glargine B/(C)×100
Clone #9F12 expressing Glargine in P. pastoris host (Fig. 4a) 2887 64 2951 2.27
GAP-KEX2 expressed in clone #9F12 (Fig. 4b) 807 797 1604 49.68
FLD1-KEX2 expressed in clone #9F12 (Fig. 4c) 231 2611 2842 91.87
The peak areas are obtained when the samples were analysed by HPLC
Data shown is average of two different experiments
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mass obtained was 6063.9 Da which compares well with the
theoretical mass and the mass of Lantus®. The peptide mass
fingerprinting data also showed that the Glargine secreted by
the P. pastoris host has appropriate disulfide linkages. The
percentage conversions of precursor to two-chain Glargine
using various constructs are tabulated in Table 5. The results
obtained clearly indicate that the endogenousKex2p produced
is not sufficient to cleave the entire quantity of expressed
single-chain precursor. Only upon co-expression of Kex2p
under strong promoter, the two-chain Glargine is being gen-
erated with a high efficiency.
We envisage that using the aforementioned strategy for
generating a two-chain-processed molecule directly into the
medium clears the hurdles involved in removing many
product-related impurities arising during downstream process-
ing in the earlier process employing trypsin. This new ap-
proach is anticipated to simplify the purification process and
reduce the cost of commercial production.
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